Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

Danica Jenine Schulte
Cedars-sinai Medical Center

Project start date: 2012-02-01

Project end date: 2014-01-31


Sponsored Links Excellgen http://Excellgen.com

Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950
Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950


Grants awarded to Danica Jenine Schulte

INNATE IMMUNITY AND MOUSE MODEL OF KAWASAKI DISEASE

Danica Jenine Schulte
Cedars-sinai Medical Center, Los Angeles, Ca 90048

Grant 5K08AI070162-04 from National Institute Of Allergy And Infectious Diseases

Abstract: Kawasaki disease (KD) is the most common form of acquired heart disease in children, both the etiology and molecular mechanisms leading to the associated coronary arteritis remain unknown. Injection of a cell wall extract derived from Lactobacillus casei; LCCWE, into mice causes coronary arteritis that is histopathologically similar to the arteritis seen in KD, yet injection of a cell wall extract from a closely related strain Lactobacillus paracasei; LpCCWE, does not. The overall goal of this project is to define the molecular mechanisms by which LCCWE causes coronary arteritis, and to explain why LpCCWE does not. Our published data indicate that LCCWE potently induces NF-kB via TLR2 and MyD88 but not TLR4 in vitro (in murine and human macrophages and ECs) and in vivo (TLR2-/- and MyD88-/- mice do not develop coronary lesions). Our recent studies in humans and mice show marked accumulation of mature dendritic cells (DCs) in clinical KD lesions and in mouse arterial lesions after inoculation with LCCWE, suggesting that DCs play an important mechanistic role in coronary arteritis in both clinical KD and in the mouse model of LCCWE-induced arteritis. The hypotheses(1) lipoteichoic acids and/or peptidoglycans specific to L. casei but not L. paracasei produce coronary arteritis but extracts from L. paracasei do not;(2) DCs are activated by these molecular components, and orchestrate immune response leading to coronary arteritis, and that DCs are essential in triggering this response. Thus, DCs may also play a similarly important function in clinical KD and could respond to DC-targeted therapies. Specific Aims(1) To define the bioactive component(s) of LCCWE that mediate inflammatory responses and coronary arteritis in this model, and to determine the molecular basis for the differences in response between L. casei and L. paracasei cell wall extracts;(2) To determine whether L. casei and/or L. paracasei cell wall extracts can induce DC activation in vitro using wild type, TLR2-/-, TLR4-/-, and MyD88-/- DCs and to explore the role of DCs in mediating coronary arteritis in vivo using a DC depletion mouse model. Significance Improved understanding of the molecular mechanisms by which LCCWE leads to coronary arteritis and the role of the innate immune system and DCs in this mouse models may yield important insights into the pathogenesis of arterial inflammatory diseases, and suggest new targets for intervention and prevention of coronary artery pathology in KD

Keywords: 0-11 years old; Acute; Affect; Aneurysm; Angiitis; Arteries; Arteritis; Atheroscleroses; Atherosclerosis; Atherosclerotic Cardiovascular Disease; Blood Vessels; Bone Marrow; CD8; CD8B; CD8B1; CD8B1 gene; Cardiac Diseases; Cardiac Disorders; Cardiac artery; Cardiovascular Diseases; Causality; Cell Communication and Signaling; Cell Extracts; Cell Maturation; Cell Signaling; Cell Wall; Cessation of life; Child; Child Youth; Childhood; Children (0-21); Clinical; Controlled Study; Coronary; Coronary artery; Data; Death; Dendritic Cells; Dendritic cell activation; Development; Disease; Disorder; Endothelial Cells; Etiology; Goals; Heart Diseases; Heart artery; Human; Human, Child; Human, General; INFLM; IP injection; Immune; Immune response; Immune system; Immunity, Innate; Immunity, Native; Immunity, Natural; Immunity, Non-Specific; Immunoglobulin Enhancer-Binding Protein; In Vitro; Inflammation; Inflammatory; Inflammatory Response; Injection of therapeutic agent; Injections; Injections, Intraperitoneal; Intracellular Communication and Signaling; Intraperitoneal Injections; Investigation; Investigators; Kawasaki Disease; L. casei; L.casei; LYT3; Lactobacillus; Lactobacillus casei; Lead; Lesion; Light; Link; Mammals, Mice; Man (Taxonomy); Man, Modern; Manuscripts; Mediating; Mediator; Mediator of Activation; Mediator of activation protein; Mice; Mice, Transgenic; Modeling; Molecular; Mucocutaneous Lymph Node Syndrome; Murein; Murine; Mus; NF-kB; NF-kappa B; NF-kappaB; NFKB; Natural Immunity; Nature; Nuclear Factor kappa B; Nuclear Transcription Factor NF-kB; Pathogenesis; Pathology; Patients; Pb element; Peptidoglycan; Photoradiation; Play; Preventive Intervention; Programs (PT); Programs [Publication Type]; Publishing; Receptor Signaling; Reporting; Research Personnel; Researchers; Reticuloendothelial System, Bone Marrow; Role; Signal Transduction; Signal Transduction Systems; Signaling; Site; Syndrome; T-Cells; T-Lymphocyte; TIL4; TLR protein; TLR2; TLR2 gene; TLR4; TLR4 gene; TOLL; Teichoic acid, lipo-; Testing; Thymus-Dependent Lymphocytes; Time; Toll-like receptors; Toll/Interleukin 1 Receptor-Like 4 Gene; Transcription Factor NF-kB; Transgenic Mice; United States; Vascular Diseases; Vascular Disorder; Vasculitis; Veiled Cells; Wild Type Mouse; arterial lesion; atheromatosis; atherosclerotic vascular disease; base; biological signal transduction; blood vessel disorder; body system, allergic/immunologic; cardiovascular disorder; children; clinical relevance; clinically relevant; cytokine; disease causation; disease etiology; disease/disorder; disease/disorder etiology; disorder etiology; hToll; heart disorder; heavy metal Pb; heavy metal lead; host response; immunoresponse; improved; in vitro testing; in vivo; insight; kappa B Enhancer Binding Protein; lipoteichoic acid; macrophage; mimicry; mouse model; nuclear factor kappa beta; organ system, allergic/immunologic; pediatric; premature atherosclerosis; prevent; preventing; preventional intervention strategy; programs; response; social role; thymus derived lymphocyte; vascular; youngster

Project start date: 2007-05-01

Project end date: 2011-04-30

Budget start date: 1-MAY-2010

Budget end date: 30-APR-2011

PFA/PA: PA-00-003

5K08AI070162-04 (2010): $129720


5K08AI070162-03 (2009): $129720

1K08AI070162-01A1 (2007): $118920